Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the Sangamo Therapeutics fourth quarter and full year 2025 teleconference call. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker today, Louise Wilkie, Head of Investor Relations and Corporate Communications. Please go ahead. Thank you. Good afternoon, everyone. Thank you for joining us on the call today. On this call are several members of the Sangamo Executive Leadership Team, including Sandy McRae, Chief Executive Officer, Natalie Dubois-Stringfellow, Chief Development Officer, Nikunj Jain, Interim Chief Financial Officer, and Greg Davis, Head of Research and Technology. Slides from our corporate presentation can be found on our website, sangamo.com, and under the Presentations page of the Investors and Media section. This call includes forward-looking statements regarding Sangamo's current expectations. These statements include, but are not limited to, Statements related to Sangamo's cash runway, Sangamo's plans to obtain additional capital and its ability to continue to operate as a going concern, the therapeutic and commercial potential and value of Sangamo's product candidates and technologies, Sangamo's ability to establish and maintain collaborations and strategic partnerships, including for its fibroid disease programme, the anticipated plans of Sangamo and its collaborators for clinical trials, regulatory submissions and regulatory approvals, and other statements that are not historical fact. Actual results may differ materially from what we discussed today. These statements are subject to certain risks and uncertainties as are discussed in our filings of the SEC, specifically in our annual report on Form 10K for the fiscal year ended December 31, 2025, a...